

Markers for bacterial infection in children with fever without source

Sergio Manzano,^{1,2} Benoit Bailey,¹ Alain Gervais,² Jocelyne Cousineau,³ Edgar Delvin,³ Jean-Bernard Girodias¹

¹Department of Pediatrics, Division of Emergency Medicine, CHU Sainte-Justine, Université de Montréal, Montréal, Quebec, Canada
²Division of Emergency Medicine, Children's Hospital HUG, Geneva, Switzerland
³Department of Clinical Biochemistry, CHU Sainte-Justine, Université de Montréal, Montréal, Quebec, Canada

Correspondence to

Benoit Bailey, Department of Pediatrics, Division of Emergency Medicine, CHU Sainte-Justine, 3175 Chemin de la Côte-Ste-Catherine, Montréal, QC H3T 1C5, Canada; benoit.bailey@umontreal.ca

Accepted 18 December 2010
 Published Online First 29 January 2011

ABSTRACT

Objectives To compare the diagnostic properties of procalcitonin (PCT), C reactive protein (CRP), total white blood cells count (WBC), absolute neutrophil count (ANC) and clinical evaluation to detect serious bacterial infection (SBI) in children with fever without source.

Design Prospective cohort study.

Setting Paediatric emergency department of a tertiary care hospital.

Participants Children aged 1–36 months with fever and no identified source of infection.

Intervention Complete blood count, blood culture, urine analysis and culture. PCT and CRP were also measured and SBI probability evaluated clinically with a visual analogue scale before disclosing tests results.

Outcome measure Area under the curves (AUC) of the receiver operating characteristic curves.

Results Among the 328 children included in the study, 54 (16%) were diagnosed with an SBI: 48 urinary tract infections, 4 pneumonias, 1 meningitis and 1 bacteraemia. The AUC were similar for PCT (0.82; 95% CI 0.77 to 0.86), CRP (0.88; 95% CI 0.84 to 0.91), WBC (0.81; 95% CI 0.76 to 0.85) and ANC (0.80; 95% CI 0.75 to 0.84).

The only statistically significant difference was between CRP and ANC (Δ AUC 0.08; 95% CI 0.01 to 0.16). It is important to note that all the surrogate markers were statistically superior to the clinical evaluation that had an AUC of only 0.59 (95% CI 0.54 to 0.65).

Conclusion The study data demonstrate that CRP, PCT, WBC and ANC had almost similar diagnostic properties and were superior to clinical evaluation in predicting SBI in children aged 1 month to 3 years.

INTRODUCTION

The introduction of the pneumococcal vaccine has significantly reduced the prevalence of serious bacterial infection (SBI) and, in particular, of occult bacteraemia in children under 3 years of age.^{1–2} Despite this, children less than 3 years of age with fever without source remain a clinical challenge as urinary tract infection (UTI), pneumonia or occult bacteraemia cannot be excluded in a well-appearing child.³ Thus, many decisions made by the clinician depend either on patient assessment or on interpretation of complementary laboratory tests.

As total white blood cells count (WBC) and absolute neutrophil count (ANC) have disappointing diagnostic properties,^{4–8} other surrogate markers of SBI have been evaluated and used in recent years. C reactive protein (CRP) and procalcitonin (PCT) were shown to be better predictors of SBI than WBC.^{4–6,7,9–11} However, the utility of these surrogate markers is not well established in

What is already known on this topic

- ▶ The pneumococcal vaccine has significantly reduced the prevalence of serious bacterial infection (SBI) in children aged under 3 with fever without source.
- ▶ Nevertheless, many clinician decisions depend on patient assessment or interpretation of complementary laboratory tests in such patients.
- ▶ The utility of surrogate markers is not well established in the postpneumococcal vaccination era.

What this study adds

- ▶ This study compared the diagnostic ability of surrogate markers and clinical evaluation to detect SBI in children vaccinated against *Streptococcus pneumoniae*.
- ▶ Based on multilevel likelihood ratios, the study suggests that these markers need to be interpreted depending on the value obtained in each patient.

the postpneumococcal vaccination era since their diagnostic properties depend on the prevalence of the disease. In addition, it is not known whether a clinical evaluation by a physician is good enough to rule out SBI when most of the SBI are now likely to be UTIs.

The objective of the present study is to compare the diagnostic properties of PCT, CRP, WBC, ANC and clinical evaluation to detect SBI in children aged 1–36 months presenting to a paediatric emergency department with fever without source, now that most of these children have been vaccinated against *Streptococcus pneumoniae*.

METHOD

Study design

This prospective cohort study was part of a randomised controlled trial (RCT) assessing the impact of a rapid semiquantitative PCT test on the management of children aged 1–36 months presenting to a paediatric emergency department with fever without source.¹² The institutional review board approved the study and written informed consent was obtained from a parent.

Settings and selection of participants

Patient enrolment took place in the emergency department of a tertiary care urban paediatric centre with 60 000 visits annually. To be included, the patient had to be a child between the ages of 1 and 36 months with a history of a rectal temperature over 38°C (100.4°F) with no identified source of infection after careful history taking and physical examination. All patients with known acquired or congenital immunodeficiency, as well as children already treated with antibiotics, were excluded. It is estimated that among eligible children, over 90% had received at least three doses of the PCV7 vaccine against *S pneumoniae* and over 97% at least two doses.^{13 14}

Study protocol

Attending paediatric emergency physicians approached the parents of children meeting the inclusion criteria to participate in the study. After consent was obtained, a blood test for complete blood count (CBC), semiquantitative PCT (for the RCT), CRP, blood culture and a bladder catheterisation or suprapubic aspiration for urine analysis and culture were performed. The attending physicians could perform any other investigations (such as lumbar puncture or chest radiography) as required and the decision to treat with antibiotics or to hospitalise was left to their discretion. A single venipuncture was performed. If this site was lost, or an insufficient amount of blood was drawn, no other attempt was made, as long as a CBC and blood culture were obtained.

The attending physicians, all paediatric emergency physicians, were asked to evaluate the SBI probability with a visual analogue scale (VAS; 0–100%) after the history had been taken and a physical examination had been carried out, but before tests results were available. This comprised the subjective clinical evaluation. Laboratory technicians were blinded to the patients' final diagnosis.

Outcome measures

The primary outcome was to compare PCT, CRP, WBC, ANC and clinical evaluation (using the VAS) to detect an SBI in children aged 1–36 months with fever without source using the receiver operating characteristic (ROC) and the area under the ROC curve (AUC).

The secondary outcomes were to define, for the group studied, (1) the best cut-off values for the selected surrogate markers, and (2) their clinical utility when the urine analysis was normal using sensitivity, specificity, positive and negative likelihood ratios, as well as positive and negative predictive values. We also aimed to evaluate the multilevel likelihood ratios of the surrogate markers and to calculate post-test probabilities of disease using the Fagan nomogram on the basis of the pretest probability of disease.¹⁵ This enabled us to overcome the limit of a single cut-off value.¹⁶

PCT and CRP measurement

One millilitre of blood was collected by venipuncture in a heparin/lithium Vacutainer (Becton-Dickinson, Franklin Lakes, New Jersey, USA) and centrifuged. Plasma was then frozen at –40°C. At the end of the RCT study, PCT was measured quantitatively with the ultra-sensitive immunoassay using TRACE (time resolved amplified cryptate emission) technology (Kryptor; Brahms, Hennigsdorf, Germany) in Geneva, Switzerland for the purpose of this cohort study. CRP was also measured for the same purpose

using a rapid immunometric method (Nycocard CRP; Axis-Shield, Oslo, Norway) according to the instructions of the manufacturer.

Definitions

- ▶ Fever without source: Rectal temperature >38°C (100.4°F) without any signs or symptoms identifying an infectious disease
- ▶ SBI: Presence of bacteraemia, UTI, pneumonia, bacterial meningitis, osteomyelitis or septic arthritis
- ▶ Bacteraemia: Positive blood culture with bacteria not considered a skin contaminant
- ▶ UTI: Any bacterial growth on urine obtained by suprapubic aspiration or $\geq 10^4$ colony forming units/ml of a single pathogen on urine obtained by bladder catheterisation
- ▶ Pneumonia: Lobar consolidation diagnosed on chest radiography confirmed by a paediatric radiologist
- ▶ Bacterial meningitis: Cerebrospinal fluid leucocytes >5 cell/ μ l and positive bacterial culture
- ▶ Osteomyelitis: Positive bone scintigraphy
- ▶ Septic arthritis: Positive bacterial culture of synovial fluid
- ▶ Normal urine analysis: <5 white blood cells with high magnification and nitrite negative.

Data analysis

The primary investigator, who recorded all important information regarding final diagnosis and laboratory tests results, reviewed the medical chart of each enrolled patient and all collection forms. He also contacted all discharged patients for a 1-week telephone follow-up. All data were entered in an Excel database (Microsoft, Richmond, Washington, USA) and analysed using SPSS (v 15.0; Chicago, Illinois, USA) and MedCalc (v 9.6.0.0; Mariakerke, Belgium).

Normally distributed data were reported as mean \pm SD. Non-normally distributed data were expressed as median and IQR. Categorical variables were reported as percentages. The diagnostic performance of PCT, CRP, WBC, ANC and clinical evaluation (using the VAS) was first evaluated by ROC analysis. The AUC were calculated for each surrogate marker and clinical evaluation. The difference between the AUC of the ROC with standard error was evaluated using MedCalc. Sensitivity, specificity, positive and negative likelihood ratios and positive and negative predictive values were reported with their 95% CI. We calculated post-test probabilities of disease on the basis of the pretest probability of disease (ie, the prevalence) and multilevel likelihood ratios. These multilevel likelihood ratios were based on the optimal cut-off obtained from our ROC analysis and other intuitive cut-offs (including previously published cut-offs).^{4 6 7 9–11 17–19} The level of significance was set a priori at $p < 0.05$.

RESULTS

Of the 457 infants and children presenting with fever without source who met the inclusion criteria between November 2006 and November 2007, and who were approached by an attending paediatric emergency physician, 328 remained in the study. Reasons for withdrawal are summarised in the study flow chart (figure 1). Table 1 summarises the clinical characteristics of the included patients. During the study, 54 children (16%) were diagnosed with SBI of whom 48 (89%) had UTIs including two with positive blood culture, four (7%) had pneumonia, one (2%) had *Neisseria meningitidis* serogroup b meningitis and one (2%)




Figure 1 Study flowchart. CRP, C reactive protein; PCT, procalcitonin; VAS, visual analogue scale.

Table 1 Clinical characteristics of the 328 patients included in the cohort study

Characteristic	n
Male (%)	165 (50)
Median age in months (IQR)	11 (6–17)
Children aged 1–6 months (%)	95 (29%)
CTAS* triage level (%)	
1	0 (0)
2	49 (15)
3	131 (40)
4	146 (44)
5	2 (1)
Mean temperature duration in hours (SD)	62 (48)
Mean maximal temperature in °C (SD)	39.6 (0.7)

*CTAS, Canadian Triage Acuity Scale.

had an occult *S pneumoniae* serotype 33 bacteraemia. Among the excluded patients, only eight had an SBI (8/112, 7.1%), all of which were UTIs.

ROC curves for PCT, CRP, WBC, ANC and clinical evaluation are shown in figure 2. The best cut-off values to detect an SBI were determined to be 0.20 ng/ml for PCT, 17.7 mg/l for CRP, $14\ 100 \times 10^6/l$ for WBC, $5200 \times 10^6/l$ for ANC and 14.8% for the VAS.

The AUC for the surrogate markers and clinical evaluation are listed in increasing order in table 2. PCT was better than clinical evaluation for detecting SBI: difference in AUC 0.22 (95% CI 0.12 to 0.33). There was no difference between PCT and CRP, WBC or ANC. CRP was better than ANC and clinical evaluation for detecting SBI: difference in AUC 0.08 (95% CI 0.01 to 0.16) and 0.28 (95% CI 0.18 to 0.38), respectively. There was no difference between CRP and WBC. WBC was better than clinical evaluation for detecting SBI: difference in AUC 0.21 (95% CI 0.11 to 0.32). There was no difference between WBC and ANC. ANC was better than clinical evaluation for detecting SBI: difference in AUC 0.20 (95% CI 0.10 to 0.31).

The SBI diagnostic accuracy of the various surrogate markers and of the clinical evaluation is presented in table 3. In the case of a normal urine analysis in the emergency department, a situation the clinician often faces, the diagnostic accuracy of the surrogate markers and of the clinical evaluation is likely to change because the relative SBI aetiologies would be different (table 4). Because an SBI was found later in 8/262 (3%) children (four pneumonias, two UTIs, one meningitis and one occult bacteraemia) with normal urine analysis in the emergency department, and confirmed by the telephone follow-up carried out 1 week after the initial visit to the emergency department, the surrogate markers had better negative predictive values.

The multilevel likelihood ratios and post-test SBI probability, assuming a pretest SBI probability of 16% (the SBI prevalence in our population), are presented in table 5. However, when the urine analysis was normal in the emergency department, the multilevel likelihood ratios and post-test SBI probability changed. In that situation, the pretest SBI probability was 3% in our study; the resulting multilevel likelihood ratios and post-test SBI probability are presented in table 6.

DISCUSSION

We report, based on similar AUCs of the different ROC curves, that in a population of children 1 month to 3 years of age presenting to a paediatric emergency department with fever without source, CRP, PCT, WBC and ANC have similar diagnostic properties for detecting an SBI and are superior to clinical evaluation based on VAS. Knowing that all physicians were experienced paediatric emergency specialists in a large tertiary hospital, it is unlikely that this is due to a lack of competence. Actually, the fact that clinical evaluation had such poor accuracy is not surprising as most of the identified SBI in our study were UTIs. Many clinical scores have been developed to detect patients at high or low risk of SBI, but generally these have been disappointing.^{4 10 17 20 21} Ancillary testing has always been recommended to help the physician detect SBI in a population such as that studied in the present report.^{17 22} Our study shows that in the postpneumococcal vaccination era, ancillary testing is even more important as the prevalence of SBI is lower than in the prevaccination period and that clinical evaluation to ascertain UTI is limited in the 1–36-month-old age group.

In our study, the ROC curves AUC are similar to those previously published. Isaacman *et al*¹⁸ and Pratt *et al*²³ found no statistical difference in AUC between CRP, WBC and ANC. These observations were confirmed by Bilavsky *et al*,²⁴ who demonstrated that there was no difference between CRP and WBC. However, using either AUC, sensitivity/specificity, positive/negative predictive values or likelihood ratios, other studies obtained better diagnostic properties for PCT and CRP than WBC and ANC.^{4 6 7 10 11 19} The difference with our study




Figure 2 Receiver operating characteristic for procalcitonin (PCT), C reactive protein (CRP), white blood cells count (WBC), absolute neutrophil count (ANC) and clinical evaluation on a visual analogue scale (VAS) to detect a serious bacterial infection in children aged 1–36 months presenting to a paediatric emergency department with fever without source.

Table 2 Area under the curves (AUC) of the receiver operating characteristic for PCT, CRP, WBC, ANC and clinical evaluation on a VAS to detect an SBI in children aged 1–36 months presenting to a paediatric emergency department with fever without source

	AUC (95% CI)
Clinical evaluation (VAS)	0.59 (0.54 to 0.65)
ANC	0.80 (0.75 to 0.84)
WBC	0.81 (0.76 to 0.85)
PCT	0.82 (0.77 to 0.86)
CRP	0.88 (0.84 to 0.91)

See text for statistical differences.

ANC, absolute neutrophil count; CRP, C reactive protein; PCT, procalcitonin; SBI, serious bacterial infection; VAS, visual analogue scale; WBC, white blood cells count.

may be explained by different inclusion criteria. We included every child with fever over 38°C without source presenting to the paediatric emergency department who required a standard work-up because of either their ill appearance or the duration of fever. Andreola *et al*⁴ and Galetto-Lacour *et al*⁷ included only children who had a temperature of over 39.5°C or who were ill-appearing, while Thayyil *et al*¹¹ included those with a temperature over 39°C . Fernández Lopez *et al*⁶ included children under 36 months of age with fever who were required to undergo blood analysis and found an SBI in 43% of their

patients. Galetto-Lacour *et al*⁷ found an SBI in 29% of children aged under 36 months with fever ($>38^{\circ}\text{C}$) without source, which is higher than usually described.^{11 18 19 23 25}

We observe optimal cut-offs derived from ROC curves that are lower for all markers than previously published. This is probably because most of our SBI were UTIs. In our study, the optimal cut-off value for CRP is 17.7 mg/l compared to 40 or 70 mg/l for prior studies.^{4 7 10 18 19} Similarly, we report an optimal cut-off value of 0.2 ng/ml for PCT, whereas in studies with a similar population, the reported cut-off for PCT ranged from 0.5 ng/ml^{6 7 11} to 0.9 ng/ml^{4 10} and was as high as 20 ng/ml in critically ill children.²⁶ The fact that the PCT cut-off apparently depends on the type of population could limit the use of the available semiquantitative test with a 0.5 ng/ml detection limit.

The WBC optimal cut-off of $14\ 100\times 10^6/\text{l}$ is similar to the traditional and preferred $15\ 000\times 10^6/\text{l}$ limit described by others and official guidelines.^{4 7 10 11 19} Finally, the ANC cut-off found in our study ($5200\times 10^6/\text{l}$) was also lower than the $10\ 000$ – $10\ 600\times 10^6/\text{l}$ usually described.^{4 18 19 23} These results are probably related again to our inclusion criteria compared with those of other studies as we previously noted.^{4 6 7 10 11 18 19}

These differences in cut-offs highlight what is in our opinion the main error in using markers. A surrogate marker has to be interpreted depending on the value obtained in each patient: the higher the result, the higher the probability of

Table 3 Diagnostic accuracy of PCT, CRP, WBC, ANC and clinical evaluation on a VAS to detect an SBI in children aged 1–36 months presenting to a paediatric emergency department with fever without source

Variable best cut-off	Sensitivity (95% CI)	Specificity (95% CI)	Positive predictive value (95% CI)	Negative predictive value (95% CI)
PCT >0.20 ng/ml	85.2 (74.4 to 92.1)	69.7 (67.6 to 71.1)	35.7 (31.2 to 38.6)	96.0 (93.1 to 97.9)
CRP >17.7 mg/l	94.4 (85.5 to 98.1)	68.6 (66.9 to 69.3)	37.2 (33.7 to 38.7)	98.4 (95.9 to 99.5)
WBC >14 100×10 ⁶ /l	81.5 (70.3 to 89.3)	70.8 (68.6 to 72.4)	35.5 (30.6 to 38.9)	95.1 (92.1 to 97.2)
ANC >5200×10 ⁶ /l	87.0 (76.5 to 93.5)	59.9 (57.8 to 61.1)	29.9 (26.3 to 32.1)	95.9 (92.6 to 97.9)
VAS >14.8%	68.5 (56.5 to 78.8)	38.7 (36.3 to 40.7)	18.0 (14.9 to 20.7)	86.2 (80.9 to 90.7)

ANC, absolute neutrophil count; CRP, C reactive protein; PCT, procalcitonin; SBI, serious bacterial infection; VAS, visual analogue scale; WBC, white blood cells count.

Table 4 Diagnostic accuracy of PCT, CRP, WBC, ANC and clinical evaluation on a VAS to detect an SBI if urine analysis was normal in the emergency department

Variable best cut-off	Sensitivity (95% CI)	Specificity (95% CI)	Positive predictive value (95% CI)	Negative predictive value (95% CI)
PCT >0.20 ng/ml	87.5 (53.6 to 97.8)	70.5 (69.4 to 70.8)	8.5 (5.2 to 9.5)	99.4 (97.9 to 99.9)
CRP >17.7 mg/l	87.5 (53.6 to 97.8)	69.7 (68.6 to 70.0)	8.3 (5.1 to 9.3)	99.4 (97.9 to 99.9)
WBC >14 100×10 ⁶ /l	75.0 (41.5 to 92.8)	71.7 (70.6 to 72.2)	7.7 (4.3 to 9.5)	98.9 (97.5 to 99.7)
ANC >5200×10 ⁶ /l	75.0 (41.4 to 92.8)	59.8 (41.5 to 92.8)	5.6 (3.1 to 6.9)	98.7 (97.0 to 99.6)
VAS >14.8%	75.0 (41.4 to 92.8)	39.4 (38.3 to 39.9)	3.8 (2.1 to 4.6)	98.0 (95.4 to 99.4)

ANC, absolute neutrophil count; CRP, C reactive protein; PCT, procalcitonin; SBI, serious bacterial infection; VAS, visual analogue scale; WBC, white blood cells count.

Table 5 Multilevel likelihood ratios and post-test SBI probability for each surrogate marker and clinical evaluation at different cut-off values

Marker and cut-off	Pretest probability (%)	LR+ (95% CI)	Post-test probability if test positive (%)	LR- (95% CI)	Post-test probability if test negative (%)
PCT >0.2 ng/ml	16	2.8 (2.3 to 3.2)	35	0.2 (0.1 to 0.4)	4
PCT >0.5 ng/ml	16	3.9 (2.6 to 5.5)	42	0.5 (0.4 to 0.7)	9
PCT >2 ng/ml	16	7.1 (3.4 to 14.9)	58	0.8 (0.7 to 0.9)	13
PCT >10 ng/ml	16	∞ (4.0 to ∞)	100	0.9 (0.9 to 1.0)	15
CRP >10 mg/l	16	2.1 (1.9 to 2.3)	29	0.1 (0.03 to 0.3)	2
CRP >17.7 mg/l	16	3.0 (2.6 to 3.2)	36	0.1 (0.03 to 0.2)	2
CRP >40 mg/l	16	4.4 (3.3 to 5.5)	46	0.3 (0.2 to 0.4)	5
CRP >80 mg/l	16	5.9 (3.5 to 9.9)	53	0.6 (0.5 to 0.8)	11
WBC >10 000×10 ⁶ /l	16	1.7 (1.5 to 1.9)	25	0.2 (0.1 to 0.5)	4
WBC >14 100×10 ⁶ /l	16	2.8 (2.2 to 3.2)	35	0.3 (0.1 to 0.4)	5
WBC >20 000×10 ⁶ /l	16	5.1 (3.2 to 7.9)	49	0.6 (0.5 to 0.7)	10
ANC >5200×10 ⁶ /l	16	2.2 (1.8 to 2.4)	30	0.2 (0.1 to 0.4)	4
ANC >10 000×10 ⁶ /l	16	3.6 (2.4 to 5.2)	41	0.6 (0.4 to 0.7)	10
ANC >15 000×10 ⁶ /l	16	5.6 (2.5 to 12.9)	52	0.8 (0.8 to 0.9)	14
VAS >14.8%	16	1.1 (0.9 to 1.3)	17	0.8 (0.5 to 1.2)	14
VAS >25%	16	1.5 (1.1 to 2.0)	22	0.7 (0.6 to 1.0)	13
VAS >50%	16	2.2 (1.1 to 4.4)	30	0.9 (0.8 to 1.0)	15

A pretest SBI probability of 16% (the SBI prevalence) was assumed. LR+, positive likelihood ratio; LR-, negative likelihood ratio.

ANC, absolute neutrophil count; CRP, C reactive protein; PCT, procalcitonin; SBI, serious bacterial infection; VAS, visual analogue scale; WBC, white blood cells count.

having an SBI. It should not only be positive or negative. This is illustrated by multilevel likelihood ratios. For example, a PCT concentration >2 ng/ml or a CRP concentration >80 mg/l raises the SBI probability from 3% to 20% if urine analysis is normal, and a PCT >10 ng/ml is diagnostic of SBI in these children (table 6). Conversely, a CRP <10 mg/l in that situation lowers SBI probability to less than 1%. This has also been reported by other authors.^{7 19 24} Thus, regardless of their respective AUC, these markers can play an important role in the decision making process when multilevel likelihood ratios are used, even when the urine analysis is normal.

In our study, UTIs were the most frequent SBI in patients, accounting for nearly 90% of all SBI. In contrast, occult bacteraemia was unusual, with only one (0.3%) occurrence. This is consistent with other postpneumococcal vaccine studies that

showed a drop in the rate of occult bacteraemia from 2–4% to less than 1%.^{2 5 8 25 27 28} The utility of blood culture in children with fever without source is more and more challenged as a result.^{2 17 25 29 30} Our study confirms that blood cultures are generally not helpful. Indeed, assuming that only 5–20% of the untreated pneumococcal occult bacteraemias will result in an SBI such as pneumonia or cellulitis and less than 2% in meningitis or sepsis, this represents only 0.05–0.2% of the well-appearing children aged 1 month to 3 years with fever without source with a 1% occult bacteraemia prevalence.^{22 31}

If the prevalence is less, as in our study, this number is even lower, reaching 0.0015–0.06%. Nevertheless, as the very young infant, not fully protected by the streptococcal vaccine, has a higher risk of bacteraemia, care must be taken in this population.³²

Table 6 Multilevel likelihood ratios and post-test SBI probability for each surrogate marker and clinical evaluation at different cut-off values if urine analysis was normal in the emergency department

Marker and cut-off	Pretest probability (%)	LR+ (95% CI)	Post-test probability if test positive (%)	LR- (95% CI)	Post-test probability if test negative (%)
PCT >0.2 ng/ml	3	3.0 (1.8 to 3.3)	8	0.2 (0.03 to 0.7)	0.6
PCT >0.5 ng/ml	3	5.6 (2.9 to 7.2)	15	0.3 (0.1 to 0.7)	0.9
PCT >2 ng/ml	3	7.9 (2.0 to 24.6)	20	0.8 (0.5 to 1.0)	2
PCT >10 ng/ml	3	∞ (8.4 to ∞)	100	0.9 (0.9 to 1.0)	3
CRP >10 mg/l	3	2.0 (1.2 to 2.6)	6	0.2 (0.04 to 0.8)	0.7
CRP >17.7 mg/l	3	2.9 (1.7 to 3.3)	8	0.2 (0.03 to 0.7)	0.6
CRP >40 mg/l	3	4.8 (2.5 to 6.1)	13	0.3 (0.1 to 0.7)	0.9
CRP >80 mg/l	3	8.5 (3.3 to 15.4)	21	0.5 (0.2 to 0.8)	2
WBC >10 000×10 ⁶ /l	3	1.7 (1.0 to 1.9)	5	0.3 (0.1 to 1.0)	0.8
WBC >14 100×10 ⁶ /l	3	2.6 (1.4 to 3.3)	7	0.3 (0.1 to 0.8)	0.9
WBC >20 000×10 ⁶ /l	3	4.3 (1.5 to 8.9)	12	0.7 (0.3 to 0.9)	2
ANC >5200×10 ⁶ /l	3	1.9 (1.0 to 2.3)	6	0.4 (0.1 to 1.0)	1
ANC >10 000×10 ⁶ /l	3	3.7 (1.5 to 6.2)	10	0.6 (0.3 to 0.9)	2
ANC >15 000×10 ⁶ /l	3	4.0 (0.7 to 18.8)	11	0.9 (0.6 to 1.0)	3
VAS >14.8%	3	1.2 (0.7 to 1.5)	4	0.6 (0.2 to 1.5)	2
VAS >25%	3	1.5 (0.6 to 2.5)	5	0.7 (0.3 to 1.2)	2
VAS >50%	3	7.5 (2.9 to 13.3)	19	0.5 (0.2 to 0.8)	2

A pretest SBI probability of 3% with normal urine analysis was assumed.

ANC, absolute neutrophil count; CRP, C reactive protein; PCT, procalcitonin; SBI, serious bacterial infection; VAS, visual analogue scale; WBC, white blood cells count.

Since urine infection is the most frequent SBI in children aged 1–36 months with fever without source, a urine analysis is considered necessary in such patients. However, the risk of SBI when the urine analysis obtained by an appropriate method (catheterisation or suprapubic aspiration) is normal in the emergency department is not well known. In this situation, surrogate markers may become useful for the clinician for detecting SBI because, as we show in this study, clinical evaluation is inferior to those markers. Because of the rarity of other SBI, surrogate markers have an excellent negative predictive value (98–99.4%) but poor positive predictive value with the optimal cut-offs when the urine analysis is normal in the emergency department.

Limitations

We considered the usual clinical diagnosis for UTI and pneumonia (positive urine culture and lobar consolidation on chest radiography). Nevertheless, studies that assessed UTI by renal ^{99m}Tc-dimercaptosuccinic acid scintigraphy show that as many as 30% of febrile UTIs are cystitis and not pyelonephritis.^{33–35} Also, viral or bacterial pneumonias can be indistinguishable.^{36–38} This could have influenced the real diagnostic properties of the markers used in our study. The study took place in a paediatric emergency department of a large tertiary hospital. As results could be different in smaller community hospitals or other settings, it is not known if the results are generalisable. Another potential limitation is that not all markers were available in every patient as some were missing in 15% (56/384) of the children included in the RCT. Finally, although the AUC is a strong descriptor to explore the diagnostic properties of a marker, it does not weigh its clinical consequence.

Conclusion

In our population of children 1 month to 3 years of age with fever without source, CRP, PCT, WBC and ANC had similar diagnostic properties to detect an SBI. Clinical evaluation was inferior to all of these markers. Although we report lower best cut-off values than previously described, a marker has to be interpreted depending on the value obtained in each patient:

the higher the result, the higher the probability of having an SBI. By reporting multilevel likelihood ratios, we showed that these markers can play an important role in the decision making process.

Funding The investigators received 200 PCT-Q kits from Brahms (Germany). Reagents for the Kryptor PCT measurements were provided by Brahms (Switzerland).

Ethics approval This study was conducted with the approval of CHU Sainte-Justine.

Competing interests None.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES

1. Black S, Shinefield H, Baxter R, *et al*. Postlicensure surveillance for pneumococcal invasive disease after use of heptavalent pneumococcal conjugate vaccine in Northern California Kaiser Permanente. *Pediatr Infect Dis J* 2004;**23**:485–9.
2. Herz AM, Greenhow TL, Alcantara J, *et al*. Changing epidemiology of outpatient bacteremia in 3- to 36-month-old children after the introduction of the heptavalent-conjugated pneumococcal vaccine. *Pediatr Infect Dis J* 2006;**25**:293–300.
3. Girodias JB, Bailey B. Approach to the febrile child: A challenge bridging the gap between the literature and clinical practice. *Paediatr Child Health* 2003;**8**:76–82.
4. Andreola B, Bressan S, Callegaro S, *et al*. Procalcitonin and C-reactive protein as diagnostic markers of severe bacterial infections in febrile infants and children in the emergency department. *Pediatr Infect Dis J* 2007;**26**:672–7.
5. Bonsu BK, Chb M, Harper MB. Identifying febrile young infants with bacteremia: is the peripheral white blood cell count an accurate screen? *Ann Emerg Med* 2003;**42**:216–25.
6. Fernández Lopez A, Luaces Cubells C, García García JJ, *et al*. Procalcitonin in pediatric emergency departments for the early diagnosis of invasive bacterial infections in febrile infants: results of a multicenter study and utility of a rapid qualitative test for this marker. *Pediatr Infect Dis J* 2003;**22**:895–903.
7. Galetto-Lacour A, Zamora SA, Gervaix A. Bedside procalcitonin and C-reactive protein tests in children with fever without localizing signs of infection seen in a referral center. *Pediatrics* 2003;**112**:1054–60.
8. Mintegi S, Benito J, Sanchez J, *et al*. Predictors of occult bacteremia in young febrile children in the era of heptavalent pneumococcal conjugated vaccine. *Eur J Emerg Med* 2009;**16**:199–205.
9. Gendrel D, Raymond J, Coste J, *et al*. Comparison of procalcitonin with C-reactive protein, interleukin 6 and interferon-alpha for differentiation of bacterial vs. viral infections. *Pediatr Infect Dis J* 1999;**18**:875–81.
10. Lacour AG, Gervaix A, Zamora SA, *et al*. Procalcitonin, IL-6, IL-8, IL-1 receptor antagonist and C-reactive protein as identifiers of serious bacterial infections in children with fever without localising signs. *Eur J Pediatr* 2001;**160**:95–100.

11. **Thayyil S**, Shenoy M, Hamaluba M, *et al*. Is procalcitonin useful in early diagnosis of serious bacterial infections in children? *Acta Paediatr* 2005;**94**:155–8.
12. **Manzano S**, Bailey B, Girodias JB, *et al*. Impact of procalcitonin on the management of children aged 1 to 36 months presenting with fever without source: a randomized controlled trial. *Am J Emerg Med* 2010;**28**:647–53.
13. **Boulianne N**, Bradet R, Audet D, *et al*. Enquete sur la couverture vaccinale des enfants de 1 an et 2 ans au Quebec en 2008. Institut National de Sante Publique du Quebec. http://www.inspq.qc.ca/pdf/publications/1045_CouverturVaccinEnfants1et2Ans2008.pdf (accessed 22 December 2010).
14. **Wals PD**, Carbon M, Sévin E, *et al*. Reduced physician claims for otitis media after implementation of pneumococcal conjugate vaccine program in the province of Quebec, Canada. *Pediatr Infect Dis J* 2009;**28**:e271–5.
15. **Fagan TJ**. Letter: Nomogram for Bayes theorem. *N Engl J Med* 1975;**293**:257.
16. **Fischer JE**, Bachmann LM, Jaeschke R. A readers' guide to the interpretation of diagnostic test properties: clinical example of sepsis. *Intensive Care Med* 2003;**29**:1043–51.
17. **Baraff LJ**, Bass JW, Fleisher GR, *et al*. Practice guideline for the management of infants and children 0 to 36 months of age with fever without source. Agency for Health Care Policy and Research. *Ann Emerg Med* 1993;**22**:1198–210.
18. **Isaacman DJ**, Burke BL. Utility of the serum C-reactive protein for detection of occult bacterial infection in children. *Arch Pediatr Adolesc Med* 2002;**156**:905–9.
19. **Pulliam PN**, Attia MW, Cronan KM. C-reactive protein in febrile children 1 to 36 months of age with clinically undetectable serious bacterial infection. *Pediatrics* 2001;**108**:1275–9.
20. **Baker MD**, Avner JR, Bell LM. Failure of infant observation scales in detecting serious illness in febrile, 4- to 8-week-old infants. *Pediatrics* 1990;**85**:1040–3.
21. **Baskin MN**, O'Rourke EJ, Fleisher GR. Outpatient treatment of febrile infants 28 to 89 days of age with intramuscular administration of ceftriaxone. *J Pediatr* 1992;**120**:22–7.
22. American College of Emergency Physicians Clinical Policies Committee. Clinical policy for children younger than three years presenting to the emergency department with fever. *Ann Emerg Med* 2003;**42**:530–45.
23. **Pratt A**, Attia MW. Duration of fever and markers of serious bacterial infection in young febrile children. *Pediatr Int* 2007;**49**:31–5.
24. **Bilavsky E**, Yarden-Bilavsky H, Ashkenazi S, *et al*. C-reactive protein as a marker of serious bacterial infections in hospitalized febrile infants. *Acta Paediatr* 2009;**98**:1776–80.
25. **Rudinsky SL**, Carstairs KL, Reardon JM, *et al*. Serious bacterial infections in febrile infants in the post-pneumococcal conjugate vaccine era. *Acad Emerg Med* 2009;**16**:585–90.
26. **Hatherill M**, Tibby SM, Sykes K, *et al*. Diagnostic markers of infection: comparison of procalcitonin with C reactive protein and leucocyte count. *Arch Dis Child* 1999;**81**:417–21.
27. **Benito-Fernández J**, Raso SM, Pocheville-Gurutzeta I, *et al*. Pneumococcal bacteremia among infants with fever without known source before and after introduction of pneumococcal conjugate vaccine in the Basque Country of Spain. *Pediatr Infect Dis J* 2007;**26**:667–71.
28. **Wilkinson M**, Bulloch B, Smith M. Prevalence of occult bacteremia in children aged 3 to 36 months presenting to the emergency department with fever in the postpneumococcal conjugate vaccine era. *Acad Emerg Med* 2009;**16**:220–5.
29. **Lee GM**, Fleisher GR, Harper MB. Management of febrile children in the age of the conjugate pneumococcal vaccine: a cost-effectiveness analysis. *Pediatrics* 2001;**108**:835–44.
30. **Stoll ML**, Rubin LG. Incidence of occult bacteremia among highly febrile young children in the era of the pneumococcal conjugate vaccine: a study from a Children's Hospital Emergency Department and Urgent Care Center. *Arch Pediatr Adolesc Med* 2004;**158**:671–5.
31. **Alpern ER**, Alessandrini EA, Bell LM, *et al*. Occult bacteremia from a pediatric emergency department: current prevalence, time to detection, and outcome. *Pediatrics* 2000;**106**:505–11.
32. **Gómez B**, Mintegi S, Benito J, *et al*. Blood culture and bacteremia predictors in infants less than three months of age with fever without source. *Pediatr Infect Dis J* 2010;**29**:43–7.
33. **Benador N**, Siegrist CA, Gendrel D, *et al*. Procalcitonin is a marker of severity of renal lesions in pyelonephritis. *Pediatrics* 1998;**102**:1422–5.
34. **Güven AG**, Kazdal HZ, Koyun M, *et al*. Accurate diagnosis of acute pyelonephritis: How helpful is procalcitonin? *Nucl Med Commun* 2006;**27**:715–21.
35. **Tuerlinckx D**, Vander Borgh T, Glupczynski Y, *et al*. Is procalcitonin a good marker of renal lesion in febrile urinary tract infection? *Eur J Pediatr* 2005;**164**:651–2.
36. **Courtroy I**, Lande AE, Turner RB. Accuracy of radiographic differentiation of bacterial from nonbacterial pneumonia. *Clin Pediatr (Phila)* 1989;**28**:261–4.
37. **Isaacs D**. Problems in determining the etiology of community-acquired childhood pneumonia. *Pediatr Infect Dis J* 1989;**8**:143–8.
38. **Korppi M**, Kiekara O, Heiskanen-Kosma T, *et al*. Comparison of radiological findings and microbial aetiology of childhood pneumonia. *Acta Paediatr* 1993;**82**:360–3.



Markers for bacterial infection in children with fever without source

Sergio Manzano, Benoit Bailey, Alain Gervaix, et al.

Arch Dis Child 2011 96: 440-446 originally published online January 29, 2011

doi: 10.1136/adc.2010.203760

Updated information and services can be found at:

<http://adc.bmj.com/content/96/5/440.full.html>

These include:

References

This article cites 37 articles, 10 of which can be accessed free at:
<http://adc.bmj.com/content/96/5/440.full.html#ref-list-1>

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections

Articles on similar topics can be found in the following collections

- [Child health](#) (1692 articles)
- [Urinary tract infections](#) (59 articles)
- [Meningitis](#) (103 articles)
- [Epidemiologic studies](#) (790 articles)
- [Immunology \(including allergy\)](#) (970 articles)
- [Infection \(neurology\)](#) (159 articles)
- [Pneumonia \(infectious disease\)](#) (94 articles)
- [Pneumonia \(respiratory medicine\)](#) (83 articles)
- [TB and other respiratory infections](#) (309 articles)
- [Urinary tract infections](#) (59 articles)
- [Urology](#) (233 articles)

Notes

To request permissions go to:

<http://group.bmj.com/group/rights-licensing/permissions>

To order reprints go to:

<http://journals.bmj.com/cgi/reprintform>

To subscribe to BMJ go to:

<http://group.bmj.com/subscribe/>